retatrutide triple agonist glp-1 gip glucagon receptors The power of three: Retatrutide's role in modern obesity and diabetes therapy Retatrutide Explained: How the Triple
Description
Balancing GLP-1 risks and benefits: physician perspectives Muscle loss is among several concerns that physicians have around GLP-1s
p = 0.0001), 12 months: 0.47 (95% CI: 0.38, 0.58
doi: 10.1016/j.amjcard.2018.02.030, PMID: [DOI] [PubMed] [Google Scholar] 29
Eating well on a GLP-1 medication doesnt have to be complicated It definitely doesnt have to be boring either
1 As the incidence of HF increases with age, the expected doubling in the number of people in the US aged 65 and older over the next decade will only exacerbate this burden
